HPV HANDBOOK - Zervita

More documents

Recommendations

Info

CERVICAL CYTOLOGY AS A SCREENING TESTReferences1. No author given. IARC Working Group on cervical cancer screening, inHakama M, Day NE, Miller AB (eds): Screening for Cancer of the UterineCervix. Lyon, IARC Scientific Publication, 19862. Coleman D, Day N, Douglas G et al. European Guidelines for QualityAssurance in Cervical Cancer Screening. Europe against cancerprogramme. Eur J Cancer 1993;29A Suppl 4:S1–383. Advisory Committee on Cancer Prevention in the European Union.Recommendations on cancer screening in the European Union. Eur JCancer 2000;36:1473–84. Hakama M, Rasanen-Virtanen U. Effect of a mass screening program onthe risk of cervical cancer. Am J Epidemiol 1976;103:512–75. Hakama M. Trends in the incidence of cervical cancer in the Nordiccountries, in Magnus K (ed): Trends in cancer incidence. Causes andpractical implications. New York, Hemisphere Publishing Corporation,1982, pp 279–926. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in theNordic countries: association with organised screening programmes.Lancet 1987;1:1247–97. Nieminen P, Kallio M, Hakama M. The effect of mass screening onincidence and mortality of squamous and adenocarcinoma of cervix uteri.Obstet Gynecol 1995;85:1017–218. Anttila A, Pukkala E, Soderman B et al. Effect of organised screening oncervical cancer incidence and mortality in Finland, 1963–1995: recentincrease in cervical cancer incidence. Int J Cancer 1999;83:59–659. Nieminen P, Kallio M, Anttila A, Hakama M. Organised vs. spontaneousPap-smear screening for cervical cancer: A case-control study. Int J Cancer1999;83:55–810. Viikki M, Pukkala E, Hakama M. Risk of cervical cancer after a negative Papsmear. J Med Screen 1999;6:103–711. Hakama M, Chamberlain J, Day NE et al. Evaluation of screeningprogrammes for gynaecological cancer. Br J Cancer 1985;52:669–7312. Hakama M. Screening, in Holland WW, Detels R, Knox G (eds): Oxfordtextbook of public health (ed 2). Oxford, New York, Toronto, OxfordUniversity Press, 199113. Koss LG. The Papanicolaou test for cervical cancer detection. A triumphand a tragedy. JAMA 1989;261:737–4321
3: <strong>HPV</strong> AND CERVICAL CANCER: PUBLIC HEALTH PERSPECTIVES14. Canadian Co-ordinating Office for Health Technology AssessmentAssessment of techniques for cervical cancer screening. CCOHTA Report2E. 1997,1–3315. Agency for Health Care Policy and Research Evaluation of cervicalcytology. Technology Assessment Report No. 5. (Available athttp://www.ahcpr.gov/clinic/tp/cervtp.htm). Agency for Health Care Policyand Research, 199916. Sigurdsson K. Quality assurance in cervical cancer screening: the Icelandicexperience 1964–1993. Eur J Cancer 1995;31A:728–3417. Anttila A, Nieminen P. Cervical cancer screening programme in Finland. EurJ Cancer 2000;36:2209–1418. Viikki M, Pukkala E, Hakama M. Risk of cervical cancer subsequent to apositive screening cytology: follow-up study in Finland. Acta ObstetGynecol Scand 2000;79:576–919. Syrjanen KJ. Spontaneous evolution of intraepithelial lesions according tothe grade and type of the implicated human papillomavirus (<strong>HPV</strong>). Eur JObstet Gynecol Reprod Biol 1996;65:45–5320. Fidler HK, Boyes DA, Worth AJ. Cervical cancer detection in BritishColumbia. A progress report. J Obstet Gynaecol Br Commonw1968;75:392–40421. Luthra UK, Prabhakar AK, Seth P et al. Natural history of precancerous andearly cancerous lesions of the uterine cervix. Acta Cytol 1987;31:226–3422. Ostor AG. Natural history of cervical intraepithelial neoplasia: a criticalreview. Int J Gyn Path 1993;12:186–9223. Linos A, Riza E, Ballegooijen M. Introduction. Cervical cancer screening.Eur J Cancer 2000;36:2175–624. Antilla A, Laara E. Cervix cancer: geographical considerations, in Sankila R,Demaret E, Hakama M, et al (eds): Evaluation and monitoring of screeningprogrammes. Brussels – Luxembourg, European Commission, EuropeAgainst Cancer Programme, 2000, pp 77–9725. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence andmortality in Europe in 1995. Eur J Cancer 2002;38:99–16626. van Ballegooijen M, van den Akker-van Marle E, Patnick J et al. Overviewof important cervical cancer screening process values in European Union(EU) countries, and tentative predictions of the corresponding effectivenessand cost-effectiveness. Eur J Cancer 2000;36:2177–8827. Miller AB. The (in)efficiency of cervical screening in Europe. Eur J Cancer2002;38:321–622
Page 4 and 5: THE HEALTH PROFESSIONAL’SHPV HAND
Page 6: ContentsList of contributors 7Intro
Page 10: Introduction to the HPV Handbook se
Page 13 and 14: 3: HPV AND CERVICAL CANCER: PUBLIC
Page 21: 3: HPV AND CERVICAL CANCER: PUBLIC
Page 26 and 27: 2. HPV testing as a screeningtest:
Page 28 and 29: HPV TESTING AS A SCREENING TEST: TH
Page 36 and 37: 3. HPV testing as a screeningtest:
Page 44: HPV TESTING AS A SCREENING TEST: TH
Page 66 and 67: THE POTENTIAL PUBLIC HEALTH IMPACT
Page 72 and 73:
THE POTENTIAL PUBLIC HEALTH IMPACT
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Indexadenocarcinoma,detection by HP
Page 82 and 83:
INDEXuse in ASCUS 53use to confirm
show all

HPV HANDBOOK - Zervita

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?